Wearables Are Writing Checks the FDA Can't Cash: The Regulatory Gap Getting Harder to Ignore
BiohackingWHOOP received $34.5 million in federal backing through the ARPA-H Prospr program. Apple Watch has FDA clearance for ECG. Clair Health is monitoring continuous hormone levels. Muse S and Cove are measuring neural activity from a headband. These are not fringe devices — they are mainstream consumer products making health claims that the regulatory framework governing them wasn’t designed to evaluate.
Where the Framework Breaks Down
The FDA’s existing medical device classification system was built around episodic interventions: a device that takes a measurement at a clinic visit, a drug administered in a defined dose for a defined condition. Wearables have introduced a different category — continuous, longitudinal, AI-driven health monitoring that accumulates data over months and surfaces patterns across sleep, recovery, hormone cycles, and cardiovascular metrics.
The conflict isn’t that wearables are dangerous in the conventional sense. It’s that the FDA, FTC, state medical boards, and consumer protection law each have partial jurisdiction over claims these devices make, with no clear resolution when those jurisdictions conflict. WHOOP received a warning letter for specific claims — not for device failure, but for the regulatory category the claims put it in. The Apple Watch ECG feature required a De Novo authorization process that took years. Newer continuous monitoring devices are navigating all of this without a clear map.
The Legislative Proposal on the Table
The THRIVE Act, proposed by the Healthspan Action Coalition and the Kitalys Institute, offers one model for resolution: a purpose-built FDA pathway for “healthspan devices” — a category that doesn’t exist today — that monitors long-term health outcomes without fitting medical device or wellness product definitions. The distinction matters because the current binary (regulated medical device vs. general wellness product) doesn’t accommodate a device that tracks sleep stages, cardiovascular strain, and hormone levels continuously and surfaces AI-generated health insights.
In January 2026, the FDA updated its general wellness guidance to expand the scope of wearables that qualify as low-risk consumer products, including some noninvasive devices estimating blood glucose for wellness purposes. This represents a deregulatory move in one direction. The THRIVE Act would create a constructive pathway in the other — not looser oversight, but a framework specifically calibrated to the continuous monitoring category.
The So What
The tension isn’t between innovation and safety — it’s between a regulatory structure built for a different era and a device category that has already scaled to millions of users. For practitioners building health stacks around wearable data, the regulatory uncertainty creates real downstream risk: a device that earns a warning letter for its claims doesn’t just face legal exposure — it faces the credibility problem of a product whose health narrative has been challenged by a federal agency. The THRIVE Act debate is worth watching precisely because it determines whether the industry gets a framework that matches what the technology is actually doing.
Photo by Ketut Subiyanto on Pexels
Source: Longevity.Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →